The responses, guidance, and advisories provided by the Pharmaceutical Advertising Advisory Board (PAAB),
including but not limited to those available through the PAAB Forum, the PAAB website, and any PAAB
correspondences, are specifically intended to assist individuals navigating the PAAB preclearance system.
Repurposing or reproducing this content without written consent from the PAAB Commissioner is strictly
prohibited. This prohibition includes, but is not limited to, use in machine learning or AI models.
170 - When introucing a new drug can we put the Health Canada classification, i.e. Angiotensin II receptor blocker or angiotensin receptor blocker of the drug on the same page as clinical information.
Claims & Support/References for Claims
1
Posts
1
Posters
268
Views
1
Watching
-
It is possible for the Health Canada pharmacological classification and claims within the limitations of the Terms of Market Authorization to appear on a single page. However, to avoid according clinical significance to the pharmacological classification, the claims will need to be presented such that they are separate and distinct messages. Call the PAAB office if you have any questions.
